# Ex Vivo Drug Sensitivity Testing and Mutation Profiling

> **NCT03860376** · — · COMPLETED · sponsor: **Florida International University** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Large Cell Lymphoma
- Refractory Childhood Acute Lymphoblastic Leukemia
- Refractory Childhood Hodgkin Lymphoma
- Refractory Childhood Malignant Germ Cell Neoplasm
- Recurrent Childhood Brain Tumor
- Recurrent Childhood Brainstem Glioma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Gliosarcoma
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03860376
- **Lead sponsor:** Florida International University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-21
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03860376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03860376, "Ex Vivo Drug Sensitivity Testing and Mutation Profiling". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03860376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*